Patents Assigned to The Whitehead Institute for Biomedical Research
-
Patent number: 8993745Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.Type: GrantFiled: September 10, 2010Date of Patent: March 31, 2015Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of MassachusettsInventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
-
Publication number: 20150072391Abstract: The present disclosure provides, in various aspects, engineered alcohol tolerant yeast and methods of producing high concentrations of ethanol.Type: ApplicationFiled: September 5, 2014Publication date: March 12, 2015Applicants: Massachusetts Institute of Technology, Whitehead Institute for Biomedical ResearchInventors: Felix Lam, Gerald Fink, Gregory Stephanopoulos
-
Patent number: 8957197Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: GrantFiled: January 18, 2011Date of Patent: February 17, 2015Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of MassachusettsInventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Patent number: 8951797Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: GrantFiled: October 5, 2012Date of Patent: February 10, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Konrad Hochedlinger
-
Patent number: 8940501Abstract: The present invention relates to methods for ligation. The invention provides novel reagents and methods for ligating an acyl donor compound with an acyl acceptor compound. Provided acyl donor compounds comprise a transamidase recognition sequence that allows ligation with a nucleophilic acyl acceptor in the presence of transamidase. The invention further provides kits comprising acyl donor compounds and optionally comprising other reagents for ligation.Type: GrantFiled: February 1, 2010Date of Patent: January 27, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Hidde L. Ploegh, John M. Antos, Maximilian Wei-Lin Popp, Carla Guimaraes
-
Patent number: 8940536Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: GrantFiled: February 9, 2010Date of Patent: January 27, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Konrad Hochedlinger
-
Patent number: 8936939Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: GrantFiled: July 23, 2012Date of Patent: January 20, 2015Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.Inventors: Tan A. Ince, Robert A. Weinberg
-
Patent number: 8932856Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: GrantFiled: October 5, 2012Date of Patent: January 13, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Konrad Hochedlinger
-
Patent number: 8933044Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.Type: GrantFiled: January 6, 2010Date of Patent: January 13, 2015Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of MassachusettsInventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
-
Publication number: 20150011611Abstract: In some aspects, methods of inhibiting survival or proliferation of a tumor cell are provided, the methods comprising inhibiting the glycine cleavage system (GCS) of the tumor cell. In some aspects, methods of treating a subject in need of treatment for a tumor, the method comprising inhibiting the GCS in the tumor. In some embodiments, the methods comprise contacting a tumor cell or tumor with a GCS inhibitor. In some embodiments, the tumor cell or tumor has elevated expression of serine hydroxymethyltransferase 2 (SH1VIT2). In some aspects, methods of identifying a tumor cell or tumor that is sensitive to inhibiting the GCS are provided, the methods comprising determining whether the tumor cell or tumor overexpresses SHMT2. In some aspects, methods of identifying a candidate anti-cancer agent are provided, the methods comprising identifying or modifying a GCS inhibitor.Type: ApplicationFiled: February 11, 2013Publication date: January 8, 2015Applicant: Whitehead Institute for Biomedical ResearchInventors: Dohoon Kim, David M. Sabatini, Richard Possemato
-
Patent number: 8927279Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: GrantFiled: October 5, 2012Date of Patent: January 6, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Konrad Hochedlinger
-
Publication number: 20140371157Abstract: Disclosed herein are novel methods and compositions useful for inhibiting interaction between a bromodomain protein and an immunoglobulin (Ig) regulatory element. The methods and compositions are particularly useful for downregulating expression of an oncogene translocated with an Ig locus, as well as for treating a cancer (e.g., hematological malignancy) characterized by increased expression of an oncogene which is translocated with an Ig locus.Type: ApplicationFiled: August 30, 2012Publication date: December 18, 2014Applicants: DANA-FARBER CANCER INSTITUTE, INC., WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Richard A. Young, Peter B. Rahl, James Bradner
-
Patent number: 8912156Abstract: The invention provides methods of targeting tumor stem cells that comprise inhibiting the level and/or activity of HDAC1, HDAC7 and phosphorylated HDAC7. The invention further provides methods for identifying tumor stem cells comprising detecting increased levels and/or activity of HDAC1, HDAC7 and phosphorylated HDAC7. Further provided are kits and articles of manufacture comprising inhibitors of the level and/or activity of HDAC1, HDAC7 and phosphorylated HDAC7. Methods for screening for inhibitors of the level and/or activity of HDAC1, HDAC7 and phosphorylated HDAC7 are also provided.Type: GrantFiled: February 2, 2012Date of Patent: December 16, 2014Assignee: Whitehead Institute for Biomedical ResearchInventors: Tan A. Ince, Tong Ihn Lee, Richard A. Young
-
Publication number: 20140357693Abstract: Aspects of the invention relate to methods and compositions for characterizing or modulating the expression of metabolic mesenchymal genes. In some embodiments, methods for assessing the expression of metabolic mesenchymal genes and related gene signatures are provided that are useful for cancer classification, prognosis, diagnosis, or treatment selection.Type: ApplicationFiled: February 25, 2014Publication date: December 4, 2014Applicant: Whitehead Institute for Biomedical ResearchInventors: Yoav D. Shaul, David M. Sabatini
-
Publication number: 20140348749Abstract: In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to glucose restriction are provided. In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to OXPHOS inhibitors are provided. In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to biguanides are provided. In some aspects, methods of identifying subjects with cancer who are candidates for treatment with an OXPHOS inhibitor are provided. In some aspects, methods of identifying subjects with cancer who are candidates for treatment with a biguanide are provided. In some aspects, methods of treating subjects with cancers that are sensitive to glucose restriction are provided.Type: ApplicationFiled: February 25, 2014Publication date: November 27, 2014Applicant: Whitehead Institute for Biomedical ResearchInventors: Kivanc Birsoy, Richard Possemato, David M. Sabatini
-
Patent number: 8895721Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.Type: GrantFiled: December 21, 2012Date of Patent: November 25, 2014Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of MassachusettsInventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
-
Patent number: 8895718Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.Type: GrantFiled: October 4, 2010Date of Patent: November 25, 2014Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of MassachusettsInventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
-
Publication number: 20140343121Abstract: MicroRNA-31 (miR-31), targets of miR-31, the role of miR-31 in inhibiting tumor metastasis, and the role of miR-31 target genes in promoting tumor metastasis are disclosed.Type: ApplicationFiled: January 8, 2014Publication date: November 20, 2014Applicant: Whitehead Institute for Biomedical ResearchInventors: Robert A. Weinberg, Scott J. Valastyan
-
Patent number: 8889706Abstract: The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORC1, mTORC2, and PI3K-related proteins. Novel methods of providing soluble mTORC1 and mTORC2 complexes are discussed, as well as methods of using the soluble complexes in a high-throughput manner to screen for inhibitory compounds.Type: GrantFiled: November 6, 2012Date of Patent: November 18, 2014Assignees: Whitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Inc.Inventors: Nathanael Gray, Jae Won Chang, Jianming Zhang, Carson C. Thoreen, Seong Woo Anthony Kang, David M. Sabatini, Qingsong Liu
-
Publication number: 20140308747Abstract: Methods and kits for expanding the number of hematopoietic stem cells are provided. The methods comprise incubating cells in medium comprising isolated IGFBP-2 and an angiopoietin-like protein (Angptl). Expanded HSCs are provided as well as culture media and kits for the expansion of human HSCs in a defined medium. Methods of administering expanded human HSCs to and individual are provided as well as methods of treating an individual by administering certain growth factors and cytokines.Type: ApplicationFiled: November 12, 2013Publication date: October 16, 2014Applicant: Whitehead Institute for Biomedical ResearchInventors: ChengCheng Zhang, Harvey Lodish